Conteltinib
Tier C — Watch / tradeConteltinib
Targets：IGF1R, ALK, FAK1, FAK2
Indications (approved)：Non-small cell lung cancer
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| Conteltinib-001 | 873-83-6 | 6-aminopyrimidine-2,4(1H,3H)-dione |
| Conteltinib-002 | 107-20-0 | 2-chloroacetaldehyde |
| Conteltinib-003 | 39929-79-8 | 7H-pyrrolo[2,3-d]pyrimidine-2,4-diol |
| Conteltinib-004 | 16372-12-6 | 6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-2,4-diol |
| Conteltinib-005 | 2139336-89-1 | 2,4-dichloro-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine |
| Conteltinib-006 | 1312162-73-4 | 2,4-dichloro-7-(4-methoxybenzyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine |
| Conteltinib-007 | 79099-07-3 | tert-butyl 4-oxopiperidine-1-carboxylate |
| Conteltinib-008 | 109-01-3Available | 1-methylpiperazine |
| Conteltinib-009 | 190964-91-1 | tert-butyl 4-(4-methylpiperazin-1-yl)piperidine-1-carboxylate |
| Conteltinib-010 | 53617-36-0 | 1-methyl-4-(piperidin-4-yl)piperazine |
| Conteltinib-011 | 448-19-1 | 4-fluoro-2-methoxy-1-nitrobenzene |
| Conteltinib-012 | 761440-65-7 | 1-(1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)-4-methylpiperazine |
| Conteltinib-013 | 761440-75-9Available | 2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)aniline |
| Conteltinib-014 | 109-86-4 | 2-methoxyethan-1-ol |
| Conteltinib-015 | 2139336-90-4 | 4-chloro-N-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-7-(4-methoxybenzyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-amine |
| Conteltinib-016 | 761435-31-8 | 2-amino-N-isopropylbenzenesulfonamide |
| Conteltinib-017 | 2139336-91-5 | N-isopropyl-2-((2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-7-(4-methoxybenzyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzenesulfonamide |
Frequently asked questions
What are the approved indications of Conteltinib?
Approved indications include: Non-small cell lung cancer.
When does the Conteltinib patent expire?
No public expiry year is available for Conteltinib yet; this page updates once verified.
How many synthesis routes are recorded for Conteltinib?
1 synthesis routes are recorded; the shortest is 11 steps with 685 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Conteltinib intermediates?
2 intermediate CAS of Conteltinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Conteltinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27